FRANKFURT, April 3 (Reuters) - Novo Nordisk

has warned that starter kits of its popular diabetes drug

Ozempic will continue to not be available in Germany during the

second quarter, urging physicians to only issue prescriptions

for patients already on the therapy.

In a statement by Novo posted on the website of German

healthcare regulator BfArM, the Danish drugmaker also urged

doctors again to only prescribe Ozempic for its approved use in

diabetes, saying that there were sufficient supplies of Wegovy,

the obesity drug that is based on the same active ingredient.